Literature DB >> 22820052

Chronic hyperdopaminergic activity of schizophrenia is associated with increased ΔFosB levels and cdk-5 signaling in the nucleus accumbens.

R Cantrup1, K Sathanantham, W J Rushlow, N Rajakumar.   

Abstract

Chronic subcortical hyperdopaminergic activity is associated with the positive symptoms of schizophrenia and is a hallmark feature of a number of animal models of the disorder. However, the molecular changes induced by increased dopaminergic activity associated with schizophrenia are not clear. Increased levels of ΔFosB have been found in association with chronic subcortical hyperdopaminergic activity following repeated cocaine or amphetamine administration. Therefore, we investigated ΔFosB signaling in a putative neurodevelopmental animal model of schizophrenia showing chronic subcortical hyperdopaminergic activity. Increased protein levels of the transcription factor ΔFosB as well as cyclin-dependent kinase-5 (cdk-5), p35, p25 and the GluR2 subunit of the AMPA glutamate receptor were observed in the nucleus accumbens (NA). Cdk-5, p35 and GlurR2 are all proteins regulated by ΔFosB, while p25 is a degradation product of p35. Increased total protein levels of cdk-5, p35 and p25 resulted in increased cdk-5 kinase activity as determined by increased phosphorylation of dopamine and adenosine regulated phosphoprotein-32 (DARPP32) at Thr(75) in the NA. DARPP32 Thr(75) is selectively phosphorylated by cdk-5 and phosphorylation of DARPP32 at Thr(75) suppresses DARPP32 activity, a critical step in the regulation of both glutamatergic and dopaminergic activity in neurons. We also found that apomorphine-induced locomotor activity was further increased following intra-accumbens infusions of roscovitine, a cdk-5 blocker, in a dose-dependent manner. Our results indicate that chronic hyperdopaminergic activity, as seen in schizophrenia, may affect glutamate and dopamine function in the NA via ΔFosB-mediated transcriptional modulation.
Copyright © 2012 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820052     DOI: 10.1016/j.neuroscience.2012.07.027

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  Infusions of Nerve Growth Factor Into the Developing Frontal Cortex Leads to Deficits in Behavioral Flexibility and Increased Perseverance.

Authors:  Sagar J Desai; Brian L Allman; Nagalingam Rajakumar
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

2.  Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel.

Authors:  George K E Umanah; Marco Pignatelli; Xiling Yin; Rong Chen; Joshua Crawford; Stewart Neifert; Leslie Scarffe; Adam A Behensky; Noah Guiberson; Melissa Chang; Erica Ma; Jin Wan Kim; Cibele C Castro; Xiaobo Mao; Li Chen; Shaida A Andrabi; Mikhail V Pletnikov; Ann E Pulver; Dimitrios Avramopoulos; Antonello Bonci; David Valle; Ted M Dawson; Valina L Dawson
Journal:  Sci Transl Med       Date:  2017-12-13       Impact factor: 17.956

3.  Metaphor in psychosis: on the possible convergence of Lacanian theory and neuro-scientific research.

Authors:  Michele Ribolsi; Jasper Feyaerts; Stijn Vanheule
Journal:  Front Psychol       Date:  2015-06-03

Review 4.  mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders.

Authors:  Larisa Ryskalin; Fiona Limanaqi; Alessandro Frati; Carla L Busceti; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2018-07-30       Impact factor: 5.923

Review 5.  The involvement of DARPP-32 in the pathophysiology of schizophrenia.

Authors:  Haitao Wang; Mohd Farhan; Jiangping Xu; Philip Lazarovici; Wenhua Zheng
Journal:  Oncotarget       Date:  2017-04-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.